Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Toru Maruyama is active.

Publication


Featured researches published by Toru Maruyama.


Aaps Pharmscitech | 2000

3ircular dichroism simulation shows a site-II-to-site-I displacement of human serum albumin-bound diclofenac by ibuprofen

Keishi Yamasaki; Mohammed Hablbur Rahman; Yasuhiro Tsutsumi; Toru Maruyama; Shamim Ahmed; Kragh-Hansen; Masaki Otagiri

1bstractPurpose: The purpose of this study was to confirm the hypothesis that a site-II-to-site-I displacement takes place when some nonsteroidal anti-inflammatory drugs are displaced by another drug from their high-affinity binding site to a site of lower affinity on human serum albumin (HSA).Methods: Diclofenac, sodium salt, was used as a representative example because of its prominent reversal of the Cotton effect. Effects of site-specific drugs on the free fraction of diclofenac were determined by equilibrium dialysis, and effects on induced circular dichroism (CD) of diclifenac bound to HSA were studied by CD and CD simulation techniques.Results: Ibuprofen, a site-II-specific drug, altered the CD spectrum of the diclofenac-HSA complex at a molar ratio of 0.5∶1 to that obtained at a higher ratio (5∶1) without ibuprofen. The induced CD spectrum obtained in the presence of ibuprofen was very similar to one that assumed that all diclofenac displaced from its high-affinity binding site (site II) became rebound to a lower-affinity site (site I). The rebinding could be influenced by a free energy linkage between the two sites which would make site I (or parts thereof) more suitable for diclofenac binding.Conclusion: We have confirmed the existence of a site II-to-site displacement, which is very striking and pharmacologically important, because the concentration of unbound drug being displaced is much lower than expected for a competitive mechanism.


CPT: Pharmacometrics & Systems Pharmacology | 2018

Modeling of the Weight Status and Risk of Nonalcoholic Fatty Liver Disease in Elderly Individuals: The Potential Impact of the Disulfide Bond‐Forming Oxidoreductase A‐Like Protein (DsbA‐L) Polymorphism on the Weight Status

Kentaro Oniki; Takehisa Watanabe; Miku Kudo; Tomoko Izuka; Tatsumasa Ono; Kazuki Matsuda; Y. Sakamoto; Katsuya Nagaoka; Tadashi Imafuku; Yu Ishima; Hiroshi Watanabe; Toru Maruyama; Koji Otake; Yasuhiro Ogata; Junji Saruwatari

Nonalcoholic fatty liver disease (NAFLD) is closely associated with obesity. Disulfide bond‐forming oxidoreductase A‐like protein (DsbA‐L) is known to be a key molecule in protection against obesity and obesity‐induced inflammation. In the present study, we used a modeling and simulation approach in an attempt to develop body mass index (BMI) and BMI‐based NAFLD prediction models incorporating the DsbA‐L polymorphism to predict the BMI and NAFLD in 341 elderly subjects. A nonlinear mixed‐effect model best represented the sigmoidal relationship between the BMI and the logit function of the probability of NAFLD prevalence. The final models for BMI and NAFLD showed that DsbA‐L rs1917760 polymorphism, age, and gender were associated with the BMI, whereas gender, patatin‐like phospholipase 3 rs738409 polymorphism, HbA1c, and high‐density and low‐density lipoprotein cholesterol levels were associated with the risk of NAFLD. This information may aid in the genetic‐based prevention of obesity and NAFLD in the general elderly population.


Archive | 2015

Glycative and oxidative modification of human serum albumin: Conformational and functional changes

Makoto Anraku; Ulrich Kragh-Hansen; Toru Maruyama; Masaki Otagiri


Archive | 2012

Preventive or therapeutic agent for chronic renal failure

Makoto Anraku; 誠 安楽; Hisao Tomita; 久夫 冨田; Toru Maruyama; 徹 丸山; Masaki Odagiri; 優樹 小田切; Yuuji Maesaki; 祐二 前崎


Archive | 2011

Structural Insights into Differences in Drug-binding Selectivity between Two Forms of Human 1 -Acid

Koji Nishi; Tomomi Ono; Teruya Nakamura; Naoko Fukunaga; Miyoko Izumi; Hiroshi Watanabe; Ayaka Suenaga; Toru Maruyama; Yuriko Yamagata; Stephen Curry; Masaki Otagiri


Abstracts of Annual meeting of Japanese Society for the Study of Xenobiotics | 2008

REDUCTION OF INDICES OF OXIDATIVE STRESS IN NORMAL SUBJECTS BY CHITOSAN SUPPLEMENTS

Makoto Anraku; Takeshi Fujii; Daisuke Kadowaki; Toru Maruyama; Masaki Otagiri; Janusz M. Gebicki; Nobuko Furutani; Hisao Tomida


Abstracts of Annual meeting of Japanese Society for the Study of Xenobiotics | 2008

PEPTIDE MOIETIES OF HUMAN ALPHA1-ACID GLYCOPROTEIN ARE INVOLVED IN LIGAND-BINDING PROPERTIES

Tomomi Ono; Koji Nishi; Naoko Fukunaga; Yasunori Iwao; Toru Maruyama; Masaki Otagiri


福山大学薬学部研究年報 = Annual report of the Faculty of Pharmacy & Pharmaceutical Sciences, Fukuyama University | 2007

アルブミンの酸化及びカルボキシメチルリジン修飾 : 透析患者における酸化ストレス亢進改善の可能性(発表論文抄録(2006))

誠 安楽; 克美 米良; 健一郎 北村; 圭介 中城; 徹 丸山; 優樹 小田切; アンラク; メラ; キタムラ; ナカジョウ; マルヤマ; オタギリ; トミタ; Makoto Anraku; Mera K; Kitamura K; Nakajou K; Toru Maruyama; Otagiri M; Tomita K


福山大学薬学部研究年報 = Annual report of the Faculty of Pharmacy & Pharmaceutical Sciences, Fukuyama University | 2007

アルブミンArg-410の酸化はアルブミンの消失を促進させる(発表論文抄録(2006))

康範 岩尾; 誠 安楽; 啓之 山崎; 恵一 川井; 徹 丸山; 優樹 小田切; イワオ; アンラク; ヤマサキ; カワイ; マルヤマ; オタギリ; Iwao Y; Makoto Anraku; Yamasaki K; Kragh-Hansen U; Kawai K; Toru Maruyama; Otagiri M


福山大学薬学部研究年報 = Annual report of the Faculty of Pharmacy & Pharmaceutical Sciences, Fukuyama University | 2007

血液透析患者における酸化アルブミンの構造と機能について(発表論文抄録(2006))

誠 安楽; 克美 米良; 健一郎 北村; 圭介 中城; 徹 丸山; 優樹 小田切; アンラク; メラ; キタムラ; ナカジョウ; マルヤマ; オタギリ; Makoto Anraku; Mera K; Kitamura K; Nakajou K; Toru Maruyama; Otagiri M

Collaboration


Dive into the Toru Maruyama's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge